Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

Michele Carbone, Prasad S. Adusumilli, H. Richard Alexander, Paul Baas, Fabrizio Bardelli, Angela Bononi, Raphael Bueno, Emanuela Felley-Bosco, Francoise Galateau-Salle, David Jablons, Aaron S. Mansfield, Michael Minaai, Marc de Perrot, Patricia Pesavento, Valerie Rusch, David T. Severson, Emanuela Taioli, Anne Tsao, Gavitt Woodard, Haining YangMarjorie G. Zauderer, Harvey I. Pass

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high-resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-asssociated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.

Original languageEnglish (US)
JournalCA Cancer Journal for Clinicians
DOIs
StatePublished - Jan 1 2019

Fingerprint

Mesothelioma
Asbestos
BRCA1 Protein
Therapeutics
Developing Countries
Incidence
Population Density
Epidemiologic Studies
Neoplasms
Mutation
Mortality

Keywords

  • asbestos
  • BRCA1-associated protein 1 (BAP1)
  • cancer syndromes
  • chromothripsis
  • gene-environment interaction
  • immunotherapy
  • mesothelioma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Carbone, M., Adusumilli, P. S., Alexander, H. R., Baas, P., Bardelli, F., Bononi, A., ... Pass, H. I. (2019). Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21572

Mesothelioma : Scientific clues for prevention, diagnosis, and therapy. / Carbone, Michele; Adusumilli, Prasad S.; Alexander, H. Richard; Baas, Paul; Bardelli, Fabrizio; Bononi, Angela; Bueno, Raphael; Felley-Bosco, Emanuela; Galateau-Salle, Francoise; Jablons, David; Mansfield, Aaron S.; Minaai, Michael; de Perrot, Marc; Pesavento, Patricia; Rusch, Valerie; Severson, David T.; Taioli, Emanuela; Tsao, Anne; Woodard, Gavitt; Yang, Haining; Zauderer, Marjorie G.; Pass, Harvey I.

In: CA Cancer Journal for Clinicians, 01.01.2019.

Research output: Contribution to journalReview article

Carbone, M, Adusumilli, PS, Alexander, HR, Baas, P, Bardelli, F, Bononi, A, Bueno, R, Felley-Bosco, E, Galateau-Salle, F, Jablons, D, Mansfield, AS, Minaai, M, de Perrot, M, Pesavento, P, Rusch, V, Severson, DT, Taioli, E, Tsao, A, Woodard, G, Yang, H, Zauderer, MG & Pass, HI 2019, 'Mesothelioma: Scientific clues for prevention, diagnosis, and therapy', CA Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21572
Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer Journal for Clinicians. 2019 Jan 1. https://doi.org/10.3322/caac.21572
Carbone, Michele ; Adusumilli, Prasad S. ; Alexander, H. Richard ; Baas, Paul ; Bardelli, Fabrizio ; Bononi, Angela ; Bueno, Raphael ; Felley-Bosco, Emanuela ; Galateau-Salle, Francoise ; Jablons, David ; Mansfield, Aaron S. ; Minaai, Michael ; de Perrot, Marc ; Pesavento, Patricia ; Rusch, Valerie ; Severson, David T. ; Taioli, Emanuela ; Tsao, Anne ; Woodard, Gavitt ; Yang, Haining ; Zauderer, Marjorie G. ; Pass, Harvey I. / Mesothelioma : Scientific clues for prevention, diagnosis, and therapy. In: CA Cancer Journal for Clinicians. 2019.
@article{d56419b472fa449b9eb8dc2b479b2d04,
title = "Mesothelioma: Scientific clues for prevention, diagnosis, and therapy",
abstract = "Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14{\%} (high-resource countries) to 50{\%} (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-asssociated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.",
keywords = "asbestos, BRCA1-associated protein 1 (BAP1), cancer syndromes, chromothripsis, gene-environment interaction, immunotherapy, mesothelioma",
author = "Michele Carbone and Adusumilli, {Prasad S.} and Alexander, {H. Richard} and Paul Baas and Fabrizio Bardelli and Angela Bononi and Raphael Bueno and Emanuela Felley-Bosco and Francoise Galateau-Salle and David Jablons and Mansfield, {Aaron S.} and Michael Minaai and {de Perrot}, Marc and Patricia Pesavento and Valerie Rusch and Severson, {David T.} and Emanuela Taioli and Anne Tsao and Gavitt Woodard and Haining Yang and Zauderer, {Marjorie G.} and Pass, {Harvey I.}",
year = "2019",
month = "1",
day = "1",
doi = "10.3322/caac.21572",
language = "English (US)",
journal = "CA Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Mesothelioma

T2 - Scientific clues for prevention, diagnosis, and therapy

AU - Carbone, Michele

AU - Adusumilli, Prasad S.

AU - Alexander, H. Richard

AU - Baas, Paul

AU - Bardelli, Fabrizio

AU - Bononi, Angela

AU - Bueno, Raphael

AU - Felley-Bosco, Emanuela

AU - Galateau-Salle, Francoise

AU - Jablons, David

AU - Mansfield, Aaron S.

AU - Minaai, Michael

AU - de Perrot, Marc

AU - Pesavento, Patricia

AU - Rusch, Valerie

AU - Severson, David T.

AU - Taioli, Emanuela

AU - Tsao, Anne

AU - Woodard, Gavitt

AU - Yang, Haining

AU - Zauderer, Marjorie G.

AU - Pass, Harvey I.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high-resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-asssociated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.

AB - Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high-resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1-asssociated protein 1 (BAP1) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.

KW - asbestos

KW - BRCA1-associated protein 1 (BAP1)

KW - cancer syndromes

KW - chromothripsis

KW - gene-environment interaction

KW - immunotherapy

KW - mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=85068712177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068712177&partnerID=8YFLogxK

U2 - 10.3322/caac.21572

DO - 10.3322/caac.21572

M3 - Review article

AN - SCOPUS:85068712177

JO - CA Cancer Journal for Clinicians

JF - CA Cancer Journal for Clinicians

SN - 0007-9235

ER -